Investor Relations Activity Record Form
Securities Code: 301277
Securities Abbreviation: Xintiandi
Announcement Number: 2026-001
Investor Relations Activity Type
☐ Specific Object Research
☐ Analyst Meeting
☐ Media Interview
☒ Performance Briefing
☐ Press Conference
☐ Roadshow
☐ On-site Visit
☐ Other (please specify other activities in text)
Participating Unit Name and Personnel
Online participation by all investors in the 2025 annual performance briefing.
Time: March 31, 2026, 15:00-16:30
Location: Value Online (https://www.ir-online.cn/)
Company Reception Personnel Names
Director and General Manager: Zhang Luwei
Financial Officer: Wang Qingkui
Board Secretary: Xie Yushan
Independent Director: Jia Faliang
Sponsor Representative: Liu Dong
Main Content of the Investor Relations Activity
- Question: The company mentioned "intermediates + APIs + formulations" integration; which area will be the focus this year?
Answer: Dear investors, as of now, the company has 13 API products registered and approved in China, with 6 API varieties submitted for registration with the National Medical Products Administration. We have over 90 associated clients in the API market, including Baiyunshan, Renhe Pharmaceutical, China National Pharmaceutical Group, and Lukang Pharmaceutical. Products like Lidocaine Hydrochloride and Naphazoline Hydrochloride have become mainstream suppliers for downstream formulation manufacturers. We have completed the US DMF filings for 2 API products and submitted 2 API products for European CEP registration, marking further alignment of our product quality system with international standards. The Vildagliptin tablets have been approved for market launch, and we aim to cover the entire chain of research and development. In 2026, we will focus on improving the quality and efficiency of API and formulation products and enhancing sales promotion efforts. We have actively built a sales and marketing system through the establishment of a CRM+AI platform, recruitment of specialized marketing personnel, and strategic cooperation with quality CSOs, laying a solid foundation for the commercialization of our products post-approval. Thank you for your attention to our company.